Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aequus PharmaceuticalsAQSZF EBITDA Margin % is 170.33% as of Sep. 2025. The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Aequus Pharmaceuticals ranks worse than 85.02% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aequus Pharmaceuticals EBITDA Margin % Related Terms
Aequus Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Aequus Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSZF vs GCAN, STEK, CBSTQ: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aequus Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aequus Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aequus Pharmaceuticals (AQSZF) has a EBITDA Margin % of 170.33% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aequus Pharmaceuticals and its competitors. According to the industry distribution chart, Aequus Pharmaceuticals ranks #817 out of 961 companies in the Drug Manufacturers industry, placing it in the top 85%.
Is Aequus Pharmaceuticals' EBITDA Margin % too high?
Aequus Pharmaceuticals' current EBITDA Margin % is 170.33%. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Aequus Pharmaceuticals' value of 170.33% is 1263.7% above this industry median. Based on the distribution chart, Aequus Pharmaceuticals ranks #817 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Aequus Pharmaceuticals' EBITDA Margin % compare to GCAN and STEK?
According to the Drug Manufacturers industry distribution chart, Aequus Pharmaceuticals ranks #817 out of 961 companies for EBITDA Margin %. This places Aequus Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Aequus Pharmaceuticals' value of 170.33% is 1263.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aequus Pharmaceuticals's current EBITDA Margin % of 170.33% is 1263.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aequus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aequus Pharmaceuticals's current EBITDA Margin % is 170.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aequus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aequus Pharmaceuticals (AQSZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 74% below its estimated fair value. The current EBITDA Margin % is 170.33% and 1263.7% above the Drug Manufacturers industry median of 12.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aequus Pharmaceuticals (AQSZF), the current EBITDA Margin % is 170.33% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSZF has been successfully added to your 
